PANTHERx Rare Pharmacy, a specialty pharmacy focused on rare and orphan diseases, announced on Monday that it has been selected by Belgium-based biopharmaceutical company UCB (EBR:UCB) as the exclusive specialty pharmacy for the distribution of KYGEVVI (doxecitine and doxribtimine) powder for oral solution (2 g/2 g).

KYGEVVI is a combination of doxecitine and doxribtimine, both pyrimidine nucleosides, indicated for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and paediatric patients with an age of symptom onset on or before 12 years. TK2d is a rare, inherited genetic disorder that affects the body's ability to produce and repair mitochondrial DNA (mtDNA). Symptoms can include muscle weakness and respiratory (breathing) failure.

PANTHERx says that it will leverage its proprietary RxARECARE model to support patients, caregivers, and prescribers with therapy-specific clinical expertise. Through individualised case management, proactive education, and comprehensive financial and insurance navigation, PANTHERx aims to help make complex rare disease therapies more personal, less overwhelming, and easier to access.